Bitcoin Generation Inc. (BTGN)

[$A-Train]

Can we make it back to .10 today?

InoLife Technologies, Inc. (OTC.BB:INOL - News), a service based healthcare products development, integration and marketing Company, announced today it will provide and market a proprietary metabolizing test to physicians and practitioners to identify how a patient's genetic makeup may affect the body's response to Plavix (colpidogrel). The test will only be made available to physicians.
The Food and Drug Administration recently announced that Plavix must now carry a so-called "black box" warning label after a landmark study revealed that patients who were "non-responders" as a result of a genetic variation were "3.58 times more likely to have a fatal stroke or myocardial infarction."
Plavix, an $8-billion-a-year drug and considered to be the second best selling drug in the world, reduces the risk of heart attack, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots. Plavix does not have its anti-platelet effects until it is metabolized into its active form by the liver enzyme, CYP2C19.